Description
Baricitinib Film-Coated Tablets (1 mg / 2 mg / 4 mg)
Healthy Inc is a specialized global supplier and exporter of advanced rheumatology, dermatology, and targeted immunomodulatory therapeutics. We provide ultra-high-purity, kinetically optimized Baricitinib Tablets, manufactured in WHO–GMP certified, high-precision specialized pharmaceutical facilities. This “Janus Kinase (JAK) Inhibitor” is a premium strategic export to rheumatology hospitals, dermatology clinics, and government health ministries, serving as the globally mandated intervention for Rheumatoid Arthritis (RA), Alopecia Areata, and Atopic Dermatitis.
Product Overview
This formulation operates as an intracellular “Signal Jammer.” Unlike injectable biologics that float in the blood to catch inflammatory proteins, Baricitinib enters the cell to stop the production of those proteins at the source.
Mechanism 1 (Selective JAK1/JAK2 Inhibition): Baricitinib reversibly inhibits the Janus Kinase (JAK) 1 and 2 enzymes. These enzymes are the “gatekeepers” for the signaling of inflammatory cytokines (like IL-6, IFN, and GM-CSF). By blocking these gates, the inflammatory message never reaches the cell’s nucleus.
Mechanism 2 (STAT Pathway Interruption): By inhibiting JAK, the drug prevents the phosphorylation and activation of STATs (Signal Transducers and Activators of Transcription). This physically halts the DNA transcription of pro-inflammatory mediators that cause joint destruction and skin inflammation.
Mechanism 3 (The “Oral Biologic” Advantage): Baricitinib offers the potency of an injectable biologic with the convenience of a Once-Daily Tablet. It has a rapid onset of action and a shorter half-life, allowing for quicker “wash-out” if a patient develops an infection—a major safety advantage over long-acting injections.
Product Composition & Strength
We supply this product as a Precision-Blended, High-Bioavailability Tablet, packed in high-barrier Alu-Alu blister strips to ensure the stability of the active API.
| Active Ingredient | Strength | Primary Clinical Function |
| Baricitinib USP/Ph.Eur. | 2 mg | The Standard RA Anchor: The primary maintenance dose for adult patients with moderate-to-severe Rheumatoid Arthritis. |
| Baricitinib USP/Ph.Eur. | 4 mg | The Dermatology/Severe Payload: High-potency dose utilized for Alopecia Areata and severe Atopic Dermatitis protocols. |
| Excipients | Proprietary Matrix | Bio-Synchronized System: Engineered to ensure a consistent pharmacokinetic profile (Tmax of approx. 1 hour) for predictable immune suppression. |
Technical & Logistics Specifications
HS Code: 3004.90.99 (Medicaments containing other active substances – Antineoplastic/Immunomodulator)
CAS Number: 1187594-09-7 (Baricitinib)
Dosage Form: Film-Coated Tablet
Packaging: Alu-Alu Blisters. Protects the sensitive API from environmental humidity across Zone IVb tropical climates.
Manufacturing Authority & Compliance
High-Potency Containment: Baricitinib is a potent immunomodulator. Our facility utilizes Dedicated High-Containment Suites with negative pressure airlocks to ensure zero cross-contamination and 100% micro-dose accuracy.
Bioequivalence Validation: We provide comprehensive dissolution and stability data to prove our generic matches the pharmacokinetic profile of the innovator brand (Olumiant), ensuring a seamless transition for chronic patients.
Primary Indications
Rheumatology: Treatment of adult patients with moderate-to-severe active Rheumatoid Arthritis (RA) who have had an inadequate response to Methotrexate.
Dermatology: Treatment of adult patients with severe Alopecia Areata (hair loss) and moderate-to-severe Atopic Dermatitis.
Emergency Medicine: Utilized under specific protocols (sometimes in combination with Remdesivir) for hospitalized COVID-19 patients requiring supplemental oxygen.
Dosage & Administration
Standard Dosing: 2 mg or 4 mg once daily, taken at the same time every day.
Administration: Can be taken with or without food.
Safety Warning: Serious Infection Risk. JAK inhibitors can increase the risk of serious viral, bacterial, or fungal infections (e.g., Herpes Zoster/Shingles). Monitor for Thrombosis (blood clots). Patients should be screened for Tuberculosis (TB) before starting therapy.
Global Export & Contract Manufacturing
Healthy Inc is a premier Specialty Pharmaceutical Exporter in India. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for next-generation JAK Inhibitors. Whether you are an Immunology Specialist Network in Africa or a B2B Pharma Marketplace partner in Southeast Asia, we ensure secure, WHO-GMP compliant delivery.
Reviews
There are no reviews yet.